Alcobra Ltd. is a public, specialty pharmaceutical company. The company is focused on the development of new medications to help patients with cognitive disorders, including attention deficit hyperactivity disorder (ADHD) and fragile X syndrome.
Alcobra is headquartered in Tel Aviv, Israel, and also has a U.S. office located outside of Philadelphia in Plymouth Meeting, Pennsylvania.
